Tscan Therapeutics is trading 7.46% down at $0.36, with the catalyst for the decline unclear.
- No new company-specific announcement dated September 8, 2026 was identified.
- The latest major development was the September 2 strategic reorganization, including a 75% workforce reduction and paused hematology programs.
- The S&P 500 and Nasdaq are down only 0.37%, below the 0.5% threshold for attributing the move to market-wide sentiment.